Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of subcutaneous Xinruibai (PEG-rhG-CSF) after chemotherapy in breast cancer
CTR20242296Phase 4Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pegfilgrastim in breast cancer, febrile neutropenia (FN), sponsored by Qilu Pharmaceutical. Started Sep 2024; status: active.
02
Drugs
pegfilgrastim
03
Conditions
breast cancerfebrile neutropenia (FN)
Beyond the preview
Go deeper on CTR20242296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242296.